Summary of randomised controlled trials found not to be published (2008–2018)
| NCT number | Trial title | Year# | Phase | Primary end-point group(s) | Secondary end-point group(s) |
| NCT00775138 | A study to determine the safety and tolerability of arikace versus placebo in patients who have bronchiectasis | 2008–2009 | 2 | Lung function, other | Lung function, microbiology, HRQoL |
| NCT01677403 | A study to access safety and efficacy of nebulized tobramycin in patients with bronchiectasis | 2012–2014 | 4 | Microbiology | Sputum, lung function, HRQoL |
| NCT01684683 | The effect of theophylline in the treatment of bronchiectasis | 2012–2014 | 4 | HRQoL | Exacerbations, sputum, HRQoL, lung function, microbiology, biomarkers, other |
| NCT01580748 | Phase 2, single group, open clinical trial to evaluate the efficacy and safety of roflumilast in symptomatic bronchiectasis patients | 2012–2013 | 2 | HRQoL | Lung function, biomarkers |
| NCT01818544 | Safety and efficacy of oral BAY85–8501 in patients with non-CF (cystic fibrosis) bronchiectasis | 2013–2014 | 2 | Other | Lung function, HRQoL, sputum, biomarkers |
| NCT01769898 | The role of theophylline plus low-dose formoterol-budesonide in treatment of bronchiectasis | 2013–2014 | 4 | HRQoL | Exacerbations, sputum, lung function, biomarkers |
| NCT02088216 | Effect of long-term, high-dose N-acetylcysteine on exacerbations of bronchiectaisis (BENE) | 2014–2016 | 4 | Exacerbations | Sputum, exacerbations, lung function, HRQoL, other |
| NCT02104245 | Phase 3 study with ciprofloxacin dispersion for inhalation in non-CF bronchiectasis (ORBIT-4) | 2014–2016 | 3 | Exacerbations | No information |
| NCT01515007 | Phase 3 study with ciprofloxacin dispersion for inhalation in non-CF bronchiectasis (ORBIT-3) | 2014–2016 | 3 | Exacerbations | No information |
| NCT02546297 | Comparisons of inhaled LAMA or ICS+LABA for COPD with bronchiectasis | 2015–2017 | 4 | Exacerbations | Lung function, HRQoL, other |
| NCT02507843 | Vitamin D as an adjunctive treatment in patients with non-cystic fibrosis bronchiectasis (VIDB) | 2015–2017 | 4 | Exacerbations | Exacerbations, HRQoL, other |
All trials were registered at clinicaltrials.gov. Primary end-points (n=12): exacerbations (n=5), health-related quality of life (HRQoL) (n=3), microbiology (n=1), other (n=2) and lung function (n=1). Secondary end-points (n=34): lung function (n=8), HRQoL (n=7), sputum (n=5), exacerbations (n=4), biomarkers (n=4), other (n=4) and microbiology (n=2). “Other” end-points include FACED score, vital signs and adverse events. LAMA: long-acting muscarinic antagonists; ICS: inhaled corticosteroid; LABA: long-acting β-agonists; COPD: chronic obstructive pulmonary disease. #: it is recommended that trials are reported within 1 year of completion, and so trials are listed here if completed earlier than November 2017.